NF2 and schwannoma: In follow-up studies, we confirmed the expression/activation of EPH receptor family tyrosine kinases as well as downstream Src family kinases in NF2-null MN and schwannoma models and reported that combining a dual mTORC1/mTORC2 inhibitor, AZD2014 or INK128 (also called TAK-228), with dasatinib is synergistic in these models (22, 23).